mr. waxman: mr. speaker, at this time i'd like to yield five minutes to my colleague and good friend from california, mrs. capps. the speaker pro tempore: the gentlelady from california is recognized for five minutes. mrs. capps: i thank my colleague for yielding and, mr. speaker, here we go again. h.r. 2 is yet another example of the majority's backward energy policy which doubles down on dirty fossil fuels instead of investing in a clean energy future. i strongly oppose it. while fossil fuels will undoubtedly be a significant part of our energy mix for years to come, they are really only one piece of a very large energy puzzle. so rather than focusing on dead-end, short-sighted policies like these, we should be considering comprehensive energy legislation that looks at the big picture. we should be investing in cutting-edge research, high-tech innovation, and new, clean energy technologies. we should be increasing energy efficiency, modernizing the electric grid. we should be promoting sustainable

mr. waxman. i wanted to ask dr. murray and mr. coukell, i know that you have worked very closely with the adopters of the death act and are strong supporters but i like to get your views on a few aspect of this legislation. first unconcern is truly drafted fda may not have adequate authority to require an untapped antibiotic labeling the way the calls attention to the fact that it's intended only for special populations. i don't think in clean secretary of state in the prescribing information is adequate and i'm concerned if those drugs are used more widely at appropriate that we could in that both harming patients and losing the effectiveness of the drugs to antibiotic resistance. what are your views about the accuracy of the language in the bill? do you agree it's critical to be a strong and prominent labeling statement to settle to find they should use the drug only in circumscribe situations? i guess we could start with dr. murray and then go to mr. coukell. >> i think it is important to have some label there. in a practical s

mr. waxman. i wanted to ask dr. murray and mr. coukell, i know that you have worked very closely with the adopters of the death act and are strong supporters but i like to get your views on a few aspect of this legislation. first unconcern is truly drafted fda may not have adequate authority to require an untapped antibiotic labeling the way the calls attention to the fact that it's intended only for special populations. i don't think in clean secretary of state in the prescribing information is adequate and i'm concerned if those drugs are used more widely at appropriate that we could in that both harming patients and losing the effectiveness of the drugs to antibiotic resistance. what are your views about the accuracy of the language in the bill? do you agree it's critical to be a strong and prominent labeling statement to settle to find they should use the drug only in circumscribe situations? i guess we could start with dr. murray and then go to mr. coukell. >> i think it is important to have some label there. in a practical s

mr. waxman for five minutes. >> thank you very much, mr. chairman. we have hearings in this committee 2010 on the problem of antibiotic resistance and the fact that it's growing and dangerous threat to public health. certainly an issue that deserves the full and complete attention of this committee. simply sure holding this hearing. our overarching goal should be to ensure that people continue to benefit from these life-saving treatments both here and the united states and around the globe. this is an inherently difficult goal to achieve. after all, when we use these antibiotics it leads to the development of pathogens that can no longer be treated by those and a by alex. rather than use it or lose it with antibiotics, kids use it and lose it. so we're great risk of losing much of the progress that has been made in fighting infection and subsequent disease. many americans die or are infected each year from antibiotic resistant microbes. we pay a high price in other ways as well, additional hospital stays, hospital readmissions, increased doctor visit

mr. waxman made the announcement, i also made mine that i would from my hat in the ring to be the lead democrat at the committee. so we have been working hard on the effort, and i'm highly encouraged. it's a long journey from the end it'snuary 2 december, but a worthwhile effort. i'm encouraged by the support i'm receiving by my colleagues. the people listening are probably wonder who -- wondering who votes on this. it will be the democrats, the new democrats that come in and be reelected democrats after the national election. so we are still working very hard, which you need to do to earn people's support, what i'm very encouraged and overwhelmingly grateful. >> does your fellow californian nancy pelosi support your bid? >> she does. >> does that help? >> i think so. i think enormously. an important such vote of confidence. this is not something she has ever done on a regular basis. i dind'dn't know she was going o do it. i think it is a blessing. eshoo, brendan sasso, thank you. >> c-span -- by america's cable companies 35 years ago and brought to you as a public service by your local cable o

mr. waxman. >> thank you, mr. chairman. i also want to say to dr. woodcock, this may be the last hearing what you and i will have the opportunity to publicly talk like this, but you've done a wonderful job at the fda, and your responses to questions from both sides of the aisle have been very, very thoughtful. i want to commend you for the work you've been doing, and thank you for it. i want to echo the comments by mr. pallone about the imports of strong labeling statement, or logo, in the context of the adapt act. i think it's essential the drugs they're a prominent statement describing the of review pathway by which they came to market. without this requirement, i'm not sure the whole thing would work to do pretty much less likely to achieve its purpose of fostering and facilitating the development of critical new antibiotics for life-threatening resistant pathogens. and additionally inappropriate or in judicious use of the drug to develop this pathway could result both in patients harm and a more rapid loss of the drug antibiotic resistance. site

mr. waxman made the announcement, i also made mine that i would throw my hat in the ring to be the lead democrate. and so we've been working hard on the effort. i'm highly encouraged. it's been, it's a long journey from the end of january to december. but it's a worthwhile effort, and so i'm encouraged by the support i'm receiving by my colleagues, the people that are listening are probably wondering when votes on this. who votes on this. it'll be the democrats, the democrats -- the new democrats that come in plus the reelected democrats after the national election. so i'm looking forward to it, and we're still working very, very hard which you need to do to earn people's support. but i'm very encouraged, and i'm overwhelmingly grateful. >> host: does your fellow californian, nancy pelosi, support your bid? >> guest: she does. >> host: does that help? >> guest: oh, i think so. i think enormously. i think e enormously. because it is, it's a, it's such an important vote of confidence. this is not something that she has ever done on a regular basis. and i didn't know that she was going to do it. an

mr. waxman, full committee ranking member is very supportive. if this bill passes this bill this evening will go to the senate and we expect them to pass it. this is one of those rare birds in this congress that actually might be signed by the president of the united states. there is no known opposition to the bill. our stakeholders, as mr. matheson pointed out. google sports it. f.c.c. supports it. microsoft, u.s. telecom, verizon, aarp are some of the more popularly known stakeholders that support the bill. i rise in strong support, mr. speaker, that we unanimously pass h.r. 3670 and send it to the senate for their consideration. and with that, i yield back. the speaker pro tempore: the gentleman yields. the question is, will the house suspend the rules and pass the bill h.r. 3670 as amended. those in favor say aye. those opposed, no. in the opinion of the chair, 2/3 being in the affirmative, the rules are suspended, the bill is passed and without objection, the motion to reconsider is laid on the table. . for what purpose does the gentleman f

mr. waxman said there are tradeoffs.ou have to balance -- there are always tradeoffs in putting these incentives in place and being a physician and scientist i'm not the most qualified person to make those tradeoffs. i think congress has to weigh those. i can tell you that the urgency, public health urgency for this problem is severe, and will continue and i think you'll hear that from other experts as well. we're not over the hump here. we have not succeeded in developing a system that will continue to generate effective new microbials. we don't have that. we have sort of heroic efforts here and there. >> thank you, dr. woodcock. my time has expired. >>> thank you, mr. chairman. both the executive order issued yesterday in the report of the president's council of advisors on science and technology emphasized the danger of antibiotic using agriculture industry and while it's clear we should do more to encourage greater research and development of new drugs it also makes sense we should be investing in efforts to limit th

mr. waxman and mr. upton for working with all of us to bring it to the floor. as well as the staffs on both sides of the aisle. as both mr. tonko and mr. gardner stated, this bill is a technical correction to existing law that will allow external power supply manufacturers to continue to sell service parts compatible with older technology to the benefit of consumers and manufacturers. it's a good piece of legislation and i would urge all the members to support this legislation. i reserve the balance of my time. the speaker pro tempore: the gentleman from kentucky reserves. the gentleman from new york is recognized. mr. tonko: mr. speaker, we have no other speakers. with that i yield back. the speaker pro tempore: the gentleman from new york yields back. the gentleman from kentucky virginia tech. mr. whitfield: i yield back the balance of my time. the speaker pro tempore: the gentleman yields back. the question is, will the house suspend the rules and pass the bill h.r. 5057, as amended. so many as are in favor say aye. those opposed no. mr. whitfield: i object

mr. waxman made the announcement i also made mine that i would throw my hat in the ring to be the lead democrat at the committee. so we have been working hard on the effort. i'm highly encouraged. it's a long journey from the end of january to december. but it's a worthwhile effort. so i'm encouraged by the support of my colleagues. the people that are listening are probably wondering who votes on this. it will be the democrats, the then new new democrats the come and plus the newly-elected democrats after the national election. i'm looking forward to it and we are still working very hard. which you need to do to earn people support. i'm very encouraged and overwhelmingly grateful. >> host: does your fellow californian nancy pelosi support your bid? >> guest: she does. i think enormously, i think enormously. because it's such an important vote of confidence. this is not something that she has ever done on a regular basis and i didn't know that she was going to do it. so it is, i think it's a blessing myself. >> host: anna eshoo, brendan sasso, thank you. >> guest: thank you. >> now nato's secre

mr. waxman said there are tradeoffs. you have to balance -- there are always tradeoffs in putting these incentives in place and being a physician and scientist i'm not the most qualified person to make those tradeoffs. i think congress has to weigh those. i can tell you that the urgency, public health urgency for this problem is severe, and will continue and i think you'll hear that from other experts as well. we're not over the hump here. we have not succeeded in developing a system that will continue to generate effective new microbials. we don't have that. we have sort of heroic efforts here and there. >> thank you, dr. woodcock. my time has expired. >>> thank you, mr. chairman. both the executive order issued yesterday in the report of the president's council of advisors on science and technology emphasized the danger of antibiotic using agriculture industry and while it's clear we should do more to encourage greater research and development of new drugs it also makes sense we should be investing in efforts to limit

mr. waxman: i yield to the gentleman, mr. green, from the state of texas. the speaker pro tempore: the gentleman is recognized for three minutes. mr. green: i ask unanimous consent to revise and extend my remarks and thank my ranking member for yielding to me. the speaker pro tempore: without objection. the gentleman is recognized. mr. green: i rise today in opposition to h.r. 2. here we are the next day after we passed bipartisan legislation with a majority on both sides that -- and now today we come up with h.r. 2 which has a combination of bills that this house has already considered. we're here the last voting day before we go home to campaign passing a bill that has zero chance of becoming law. h.r. 2 is an affront to the bipartisan work we've done in the energy and commerce committee over the past year -- commrge and commerce committee. over the past year, members of our committee have worked to draft legislation that would supply the dramatic renaissance our country is experiencing. h.r. 2 is not reflective of this hard work. instead of working to im

mr. waxman and others, but the ideas need to come in because we really do want to do this right. and lots of shoulders, we're going to be leaning on to make sure that it happens and we're most grateful for the administration's support too. peggy, you've done a good job, you realize constructively where we need to go, sylvia burrwell said again confirmed that the administration's support for this, reaching out to the senate, doctor cor. collins has superstar in traveling to different parts of the country. and michael, your work again, we stole a lot from you over the last couple of years and just outstanding work that you have done and committed in the foundation and the organization that you have has truly helped us. great entrepreneurs bill parfitt and dean cameron, thank you for your work and two weeks ago in colorado, but now, we're very grateful for that assistance and we're going to turn the green light on in this green room. thank you. >> thank you. >>> coming up tonight on cspan 3 former virginia democratic senator jim webb. later remarks by british labor leader ed milliba

mr. waxman for five minutes. >> thank you very much. we have hearings in this committee in 2010 on the problem of antibiotic resistance and the fact that it's a growing and dangerous threat to public health. it certainly is an issue that deserves the full and complete attention of this committee so i'm pleased you're holding this hearing. our overarching goal is to assure people can continue to benefit from these life-saving treatments here in the united states and around the globe. this is a difficult goal to achieve. after all when we use these antibiotics it leads to the development of pathogens can no longer be treated by those antibiotics. rather than use it or lose it with antibiotics it's use it and lose it. so we're at great risk of losing much of the progress that has been made in fighting infection and subsequent disease. many americans die each year. we pay a high price in other ways as well for hospital stays, moment readmissions, increased doctor visits. all at unnecessarily to the nation's angel health care bill. it will t